BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach

Status Withdrawn

Clinical Trial Summary

The investigator's aim in this study is to evaluate the impact of a new standard of care protocol for the treatment of BK viremia and nephropathy (BKVAN), which includes switching from Tacrolimus to equivalent dose of Cyclosporine in patients who have been diagnosed with BK viremia or BKVAN based on their viral load, overall graft function (estimated glomerular filtration rate), acute rejection, and rate of graft loss due to rejection or BKVAN.

Clinical Trial Description

This study will be a combined retrospective chart review and prospective observational study. This will be a single center project that will take place at Loma Linda University Transplant Institute. All adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant and meet the inclusion criteria but no exclusion criteria will be enrolled and observed per study protocol.

All kidney transplant recipients are routinely assessed for BK virus nephropathy and viremia post transplant as part of their standard care. Patients with BK viremia or BK virus nephropathy will have adjustments in their immunosuppressive medication based on current guidelines and recommendations which include reduction in immunosuppression, treatment with medications with antiviral activity (Cidofovir, Ciprofloxacin, Leflunomide, IVIG) or switching from a Tacrolimus (Prograf)-based regimen to a Cyclosporine-based regimen. Retrospectively, the investigator will collect data on patients who have been diagnosed with BK viremia or BK virus nephropathy and have had such a management in past 66 months (from 1/1/2010 till 06/30/2015). Prospectively, the investigator will enroll and collect data on patients who will be treated for BK viremia or BK virus nephropathy.

As standard of care, all kidney transplant recipients will be seen routinely on weekly-biweekly basis in post-transplant clinic for up to 3 months then every 3 months for up to a year and yearly thereafter. All kidney transplant recipients will be monitored for BK viremia by having blood PCR tested on a monthly basis at 1, 2, 3, 6, and 12 months after transplant. Also, all patients post-kidney transplant will be tested for BK viremia if there is an acute rise in their creatinine. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02758288
Study type	Observational
Source	Loma Linda University
Contact
Status	Withdrawn
Phase
Start date	September 2015
Completion date	July 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01624948` - Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients	Phase 4
Active, not recruiting	`NCT05026021` - Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia
Recruiting	`NCT05511779` - Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation	Phase 2
Recruiting	`NCT05183490` - R-MVST Cells for Treatment of Viral Infections	Phase 1
Active, not recruiting	`NCT00684372` - BK Viremia After Renal Transplantation	N/A
Recruiting	`NCT06219616` - Prediction of BK Virus Reactivation in Kidney Transplant Recipient	N/A
Not yet recruiting	`NCT05264259` - New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
Terminated	`NCT05305040` - Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant	Phase 2/Phase 3
Completed	`NCT04605484` - Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia	Phase 2
Terminated	`NCT04390113` - Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)	Phase 3
Withdrawn	`NCT02313844` - Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)	Phase 1
Completed	`NCT03532971` - Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
Recruiting	`NCT02479698` - Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus	Phase 2
Recruiting	`NCT05101213` - Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients	Phase 1
Completed	`NCT01789203` - Ciprofloxacin for Prevention of BK Infection	Phase 4
Completed	`NCT04693637` - Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant	Phase 2/Phase 3
Recruiting	`NCT05618275` - Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS
Recruiting	`NCT04542733` - The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient	N/A
Recruiting	`NCT05042076` - BK With VST for Kidney Transplant Patients	Phase 1
Completed	`NCT04294472` - A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients	Phase 2